Hint: Mr. CTLA-4 Himself, Dr. Luis Camacho in Texas!!!!
Back In 2005:
On 10-24-2005 when I was first diagnosed with melanoma, I contacted Dr. Luis H. Camacho who was currently at MD Anderson.
Subject: Paper on Antitumor Activity
“Luis Camacho, My name is Jim Breitfeller and I have recently been diagnosed with melanoma will need some sort of Ontological therapy after my surgery. I ran across an abstract of yours (Antitumor activity in Melanoma and anti-self responses in Phase 1 trials with the anti-Cyctotoxic T Lymphocyte-Associated Antigen 4 Monoclonal Antibody CP-675,206) in the Journal of Clinical Oncology. Is it possible to get a copy of your paper? It can be emailed to the address below.”
Camacho response:
Dear James,
Thank you for your note. The CTLA4 antibodies in melanoma are currently under development and completing the approval process with the FDA (Phase II and Phase III). The overall response rates in my mind will be near 20-30% with a good number of patients attaining long term remissions. However, none of the programs are currently oriented to patients rendered NED (Stage III or IV). They are in fact for patients with advanced disease. From your brief introduction, I think your best options are to obtain an HLA typification and go for an adjuvant trial.
Please feel free to page me if you need further information. Pager is 713.404-5319
Best,
Luis
CP-675,206, a novel monoclonal antibody, enlists the immune system to fight advanced melanoma
Today:
Dear Jim,
Thanks for your note. You really refreshed my mind! I am glad things have worked out relatively well for you!. Did you get rid of your disease?. I am glad you are writing your story and hopefully inspiring a number of patients in dire need of hope. Let me know how can I help.
Kindest regards,
Luis
Now I can hopefully get Dr. Camacho to propose a Clinical Trial based on my success. This my Dream. As Bruce Springstein "I am working on a Dream".
And If I have the research right it may be one of the paths to the "YELLOW BRICK ROAD"
Jimmy B
No comments:
Post a Comment